Sun Dips Toe Into Vaccines With Dengvaxia Challenge

India's top-ranked drug firm Sun Pharma is vying for a play in the dengue vaccines space via a collaboration with the non-profit research organization, International Centre for Genetic Engineering and Biotechnology. The partners expect their vaccine candidate to potentially best live-attenuated dengue vaccine candidates, including Sanofi's Dengvaxia.

Sun Pharmaceutical Industries Ltd. and the International Centre for Genetic Engineering and Biotechnology (ICGEB) have started a new collaboration to develop a vaccine targeted against all the four serotypes of the dengue virus; these plans supplement the duo's earlier alliance for a botanical drug targeting dengue.(Also see "Sun’s ‘Game Changing’ Dengue Drug May Launch In Four Years" - Scrip, 12 May, 2016.)

ICGEB, a joint statement from the partners said, has developed a tailored recombinant virus-like-particle (VLP)-based tetravalent dengue vaccine, containing host-receptor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

More from Scrip

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.